

Abiomed CEO Shrugs off Impact of DoJ Probe, FDA Call

Mass Device

A U.S. Justice Dept. investigation and the FDA's decision to require pre-market approval for Abiomed's Impella heart pump leave CEO Michael Minogue unfazed.



Cardiologists aren't paying much attention to the noise around [Abiomed](#) [1] (NSDQ:[ABMD](#) [2]) and its flagship medical device, the Impella heart pump, at least according to chairman, president & CEO Michael Minogue.

That noise centered around a pair of events during the 4th quarter: news of a U.S. Justice Dept. probe into its marketing of the Impella pump and an FDA decision to require the device to undergo a more rigorous approval process.

The Danvers, Mass.-based medical device company [revealed the DoJ probe last year](#) [3], sending share prices down more than 30% in a day. A month later a federal watchdog agency panel [voted to require that the Impella undergo the FDA's pre-market approval protocol](#) [4], which ordinarily requires extensive clinical trials before approval is granted.

Source URL (retrieved on 01/26/2015 - 4:24am):

<http://www.mdtmag.com/news/2013/02/abiomed-ceo-shrugs-impact-doj-probe-fda-call>

Links:

[1] <http://www.massdevice.com/company/abiomed-inc>

[2] <http://www.google.com/finance?q=abmd>

[3] <http://www.massdevice.com/news/abiomed-plunges-30-federal-investigation-impella-marketing>

[4] <http://www.massdevice.com/news/fda-panel-decision-means-abiomed-will-need-new-pma-impella-pump>